Search | Clinical Trials Finder

Conditions: Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions: Nitric Oxide Gas, Standard Care Arm; Drug
Lead sponsor: Xijing Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 242
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more

Conditions: Coronary Artery Disease
Interventions: Bradykinin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Inotropy, Fluid Management, Cardiac Event, Perioperative Cardiac Risk, Vascular Resistance, Hemodynamic Monitoring, Hemodynamic Management, Fluid Responsiveness
Interventions: RESIPI Management Strategy, No intervention; Procedure · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Coronary Syndrome
Interventions: Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years and older
Enrollment: 3,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 91
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more

Conditions: Coronary Artery Disease
Interventions: Colchicine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Birmingham, Alabama • Long Beach, California • Gainesville, Florida + 6 more

Conditions: Cardiovascular Primary Prevention Strategy
Interventions: Coronary Artery Calcium Screening and Statin Treatment, Standard Treatment; Combination Product · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 50 Years to 80 Years
Enrollment: 5,765 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Ventricular Dysfunction, Left, Major Adverse Cardiac Events
Interventions: EGHEM; Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 70 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Obesity, Overweight
Interventions: NB32, PBO, Weight Management Program; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 45 Years and older
Enrollment: 8,910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 224
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more

Conditions: Acute Coronary Syndrome
Interventions: Apolipoprotein A-I [human] (apoA-I), Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 18,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 202
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more

Conditions: Myocardial Infarction, Acute
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions: Tirzepatide, Dulaglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 44,671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy Complications, Cardiovascular
Interventions: Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.; Other
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Atherosclerosis
Interventions: Selnoflast, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Beverly Hills, California • Irvine, California • Santa Rosa, California + 18 more

Conditions: Cardiac Events
Interventions: Index Event; Device
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 23 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Detroit, Michigan • Kettering, Ohio

Conditions: Coronary Artery Disease
Interventions: Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 25,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 178
States / cities: Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more

Conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 136
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 122 more

Conditions: Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions: Cipherome Lighthouse Pilot; Diagnostic Test
Lead sponsor: Cipherome, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Edinburg, Texas

Conditions: Preoperative Care, Surgery--Complications, Myocardial Infarction
Interventions: Not listed
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM); Other
Eligibility: 45 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Winston-Salem, North Carolina • Cleveland, Ohio • Houston, Texas

Conditions: Ischemic Heart Disease
Interventions: Laboratory Biomarker Analysis, Patient Activity, Questionnaires; Other · Device · Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 105 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Adverse Cardiac Event (MACE)
Interventions: Personal Information Disclosure; Behavioral
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Acute Kidney Injury, Fluid Overload, Ultrasonography
Interventions: Portal vein flow, Intra-renal flow, Hepatic vein flow, Pulmonary B-lines, Dimensions of the inferior vena cava, Left ventricular function, Right ventricular function; Diagnostic Test
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM); Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Atherosclerosis
Interventions: Darapladib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15,828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 155
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more

Search by objective public record fields.

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial

Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events

Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

MACE CDS Software Master Enrollment Protocol

The Dual Antiplatelet Therapy Study (DAPT Study)

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring

How Clinical and Personal Information Shape Physicians' Risk Judgments

Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial